Healthcare Industry News: hereditary angioedema
News Release - April 24, 2008
Jerini AG -- FDA Issues Not Approvable Letter for Icatibant in the Treatment of HAEJerini Expects CHMP Opinion for European Marketing Authorization Later Today
BERLIN, April 24, 2008 (Healthcare Sales & Marketing Network) -- Jerini AG (FSE:JI4) has received a not approvable letter from the FDA for its New Drug Application (NDA) for Icatibant in the treatment of hereditary angioedema (HAE). The not approvable letter outlines areas of concern that the company is now going to review with the agency.
Jerini is expecting an opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) for Icatibant in the treatment of HAE later today.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.